Todd C Zion from Salem, MA, age 49

Resumes

Todd Zion

view source

Location:

Greater Boston Area

Industry:

Biotechnology

Us Patents

Polymer Particles Of Controlled Shape
view source
US Patent:

6380297, Apr 30, 2002
Filed:

Aug 12, 1999
Appl. No.:

09/373340
Inventors:

Todd C. Zion - Rochester NY
Dennis E. Smith - Rochester NY
Hichang Yoon - Fairport NY
Matthew C. Ezenyilimba - Walworth NY
Assignee:

NexPress Solutions LLC - Rochester NY
International Classification:

G08L 334
US Classification:

524493, 430110, 430111, 430137, 524315, 524501, 524500, 524502, 524560, 524561, 524576, 524577, 524579, 524580, 524581, 524583, 524585, 524602, 524672, 524546
Abstract:

A method for the preparation of polymer particles comprising the steps of: a) forming an organic phase by dissolving a polymer material in a solvent; b) dispersing the organic phase in an aqueous phase comprising a particulate stabilizer and homogenizing the resultant dispersion, thereby forming spherical particles having a selected particle and uniform particle size distribution; c) following the homogenizing, adding a particle shape-modifying surface active material to the spherical particles; and d) removing the solvent, thereby producing irregularly shaped polymer particles having substantially the same selected particle size and particle size distribution as that of the spherical particles.

Toner Particles Of Controlled Morphology
view source
US Patent:

6482562, Nov 19, 2002
Filed:

Aug 31, 2001
Appl. No.:

09/944583
Inventors:

Matthew C. Ezenyilimba - Rochester NY
Michael T. Regan - Fairport NY
Todd C. Zion - Rochester NY
Dennis E. Smith - Rochester NY
Hichang Yoon - Fairport NY
Assignee:

Eastman Kodak Company - Rochester NY
International Classification:

G03G 908
US Classification:

43013714, 4301371
Abstract:

A method for the preparation of electrostatographic toner comprising the steps of: a) dissolving a polymer material in an organic solvent to form an organic phase; b) dispersing the organic phase in an aqueous phase comprising a particulate stabilizer to form a dispersion and homogenizing the resultant dispersion wherein a flocculating agent is added to the aqueous phase before or after homogenization; c) evaporating the organic solvent and recovering a resultant product; and d) washing and drying the resultant product.

Stimuli-Responsive Systems For Controlled Drug Delivery
view source
US Patent:

7531191, May 12, 2009
Filed:

Dec 17, 2003
Appl. No.:

10/740436
Inventors:

Todd C. Zion - Allston MA, US
Andrey Zarur - Winchester MA, US
Jackie Y. Ying - Winchester MA, US
Assignee:

Massachusetts Institute of Technology - Cambridge MA
International Classification:

A61K 9/10
A61K 9/14
US Classification:

424488, 424486, 424489
Abstract:

A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

Methods For Reducing The Mitogenicity Of Lectin Compositions
view source
US Patent:

7687608, Mar 30, 2010
Filed:

Oct 19, 2006
Appl. No.:

11/583993
Inventors:

Thomas M. Lancaster - Stoneham MA, US
Wenyi Cai - Somerville MA, US
Ryan Faucette - Somerville MA, US
Matthew Pecukonis - Salem MA, US
Todd C. Zion - Marblehead MA, US
Assignee:

SmartCells, Inc. - Berverly MA
International Classification:

C07K 16/00
A61K 6/14
A61K 35/00
G01N 33/53
US Classification:

530396, 525 541, 514 3, 424486, 424124, 424 935, 436827
Abstract:

Methods for reducing the T-cell mitogenicity of lectin compositions are provided. In one aspect this is achieved by chemically modifying mitogenic lectin compositions under optimized conditions. Additionally or alternatively, the reduction in T-cell mitogenicity is achieved by removing unmodified subunits chemically modified mixtures. Modified lectin compositions with reduced T-cell mitogenicity are also provided as are uses of the inventive compositions.

Stimuli-Responsive Systems For Controlled Drug Delivery
view source
US Patent:

8062668, Nov 22, 2011
Filed:

Mar 31, 2009
Appl. No.:

12/415432
Inventors:

Jackie Y. Ying - Winchester MA, US
Todd C. Zion - Marblehead MA, US
Andrey Zarur - Winchester MA, US
Assignee:

Massachusetts Institute of Technology - Cambridge MA
International Classification:

A61K 9/10
A61K 9/14
US Classification:

424488
Abstract:

A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

Stimuli-Responsive Systems For Controlled Drug Delivery
view source
US Patent:

8357400, Jan 22, 2013
Filed:

Nov 21, 2011
Appl. No.:

13/301049
Inventors:

Jackie Y. Ying - Winchester MA, US
Todd C. Zion - Marblehead MA, US
Andrey Zarur - Winchester MA, US
Assignee:

Massachusetts Institute of Technology - Cambridge MA
International Classification:

A61K 9/10
A61K 9/14
US Classification:

424488, 424486, 424489, 424490, 424493
Abstract:

A method of delivering a therapeutic agent by providing a cross-linked polymer encapsulating the therapeutic agent to a site in a patient. The degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades.

Soluble Non-Depot Insulin Conjugates And Uses Thereof
view source
US Patent:

8569231, Oct 29, 2013
Filed:

Jan 27, 2010
Appl. No.:

13/257507
Inventors:

Todd C. Zion - Marblehead MA, US
Thomas M. Lancaster - Stoneham MA, US
Assignee:

Smartcells, Inc. - Rahway NJ
International Classification:

A61K 38/28
A61P 3/10
US Classification:

514 59, 514 63, 514 69
Abstract:

In one aspect, the disclosure provides a conjugate comprising an insulin molecule having an A-chain and a B-chain; an affinity ligand covalently bound to the A-chain; and a monovalent glucose binding agent covalently bound to the B-chain, wherein the affinity ligand competes with glucose for non-covalent binding with the monovalent glucose binding agent. In the absence of glucose, the monovalent glucose binding agent binds the affinity ligand to produce a “closed” inactive form of the insulin molecule. When free glucose is added, it competes with the affinity ligand for binding with the monovalent glucose binding agent to produce an “open” active form of the insulin molecule. The monovalent glucose binding agent and affinity ligand are covalently bound to the insulin molecule. The disclosure also provides methods of using these conjugates and methods of making these conjugates. In another aspect, the disclosure provides exemplary conjugates.

Polynucleotide Aptamer-Based Cross-Linked Materials And Uses Thereof
view source
US Patent:

8603529, Dec 10, 2013
Filed:

Jan 27, 2010
Appl. No.:

13/145531
Inventors:

Todd C. Zion - Marblehead MA, US
Thomas M. Lancaster - Stoneham MA, US
Assignee:

Smartcells, Inc. - Rahway NJ
International Classification:

A61K 9/14
A61K 38/28
C07H 21/04
US Classification:

424486, 536 231, 530303, 514 59, 514 68
Abstract:

In one aspect, the disclosure provides cross-linked materials that include multivalent polynucleotide aptamers that bind a target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with the target molecule for binding with the aptamers and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between aptamers and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of the target molecule. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label. The drug, detectable label and affinity ligands may be covalently or non-covalently bound to the conjugate framework.